Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: An analysis of change in iPTH and accordance to KDOQI recommendations

American Journal of Nephrology

Volumn 29, Issue 2, 2009, Pages 71-78

  Kumar, Neil ^a,e   Lindberg, Jill ^b   David, Kristin ^c   Morris, Jonathan ^c   Menoyo, José ^d  

^a Kidney and Hypertension Center PC   (United States)

^b New Orleans Nephrology Associates   (United States)

^c ProSanos Corporation   (United States)

^d GENZYME CORPORATION   (United States)

^e Kidney and Hypertension Center PC   (United States)

Author keywords

Active vitamin D; CKD stage 3; CKD stage 4; Doxercalciferol; Hypercalcemia; Secondary hyperparathyroidism

Indexed keywords

DOXERCALCIFEROL; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INCIDENCE; INFORMATION PROCESSING; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MINERAL METABOLISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; SECONDARY HYPERPARATHYROIDISM;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCIUM; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES;

EID: 48749093434     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151275     Document Type: Article

References (16)

1. Craver L, Marco MP, Martínez I, Rue M, et al: Mineral metabolism parameters throughout chronic kidney disease stages 1-5 - achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007;22:1171-1176.
2. Sherrard DJ, Hercz G, Pei Y, Maloney NA, et al: The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int 1993;43:436-442.
3. Salem MM: Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis 1997;29:862-865.
4. Andress DL: PTH in CKD Stages 3 and 4: The Need for Early Testing and Treatment. Improving Clinical Outcomes for Hemodialysis Patients in the International Dialysis Outcomes and Practice Pattern Studies (DOPPS). American Society of Nephrology Renal Week 2005, Philadelphia, November 8-13, 2005.
5. Sherrard DJ, Hercz G, Pei Y, et al: The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993;43:436-442.
6. Fukagawa M, Kazama JJ, Kurokawa K: Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant 2002;17(suppl 10):2-5.
7. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999;56:383-392.
8. Randon RB, Rohde LE, Comerlato L, Ribeiro JP, Manfro RC: The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis. Braz J Med Biol Res 2005;38:1409-1416.
9. Raggi P, Boulay A, Chasan-Taber SC, et al: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
10. Salgueira M, Del Toro N, Moreno-Alba R, Jimenez NA, Palma A: Vascular calcification in the uremic patient: a cardiovascular risk? Kidney Int 2003(suppl):S119-S121.
11. Kestenbaum B, Belozeroff V: Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest 2007;37:607-622.
12. K/DOQI Clinical Practice Guidelines for Bone Metabolism, and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003;42:S1-S201.
13. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, et al: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858-1865.
14. Young EW, Akiba T, Albert JM, McCarthy JT, et al: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:34-38.
15. Dennis VC, Albertson GL: Doxercalciferol treatment of secondary hyperparathyroidism. Ann Pharmacother 2006;40:1955-1965.
16. Hectorol® - doxercalciferol capsules 2.5 μg. Genzyme, Cambridge/MA, USA.